The last Congress of the Spanish Society of Diabetes has given for many things, one of them has been the interesting conversation with the Endocrine of the Francesc de Borja Hospital in Gandia, Dr. Paolo Rossetti, who advanced some of the most important novelties in theTheme of new insulins.
Up to three types of new basal insulins, some already marketed, have been created to improve the quality of life and glycemic control of people with diabetes.In this sense, one of the first things that the endocrine did at the beginning of the interview was to thank the researchers and the pharmaceutical industry of this type of advance in new insulins.
In Dr. Rossetti's words, the new insulins are going to penetrate a more physiological replacement for insulin production with lower risks of hypoglycemia in the patient with diabetes.
That is, being flatter and more homogeneous insulins during the day hypoglycemia can be reduced by 25% and 30% of cases, according to endocrine.
These new insulins are for example the swallowing or sticky lispro, two examples of new insulins that intend to maintain the effect throughout the day, thus improving glycemic control.Then we leave the interview held with Dr. Paolo Rossetti who deepens all issues related to new insulins.
Another of the issues that Rossetti commented and that leaves in the air of our partner Dani Royo, is that it can be done to delay the moment of insulin infusion in patients with type 2 diabetes, who normally begin with oral to endinsulin.
Dr. Rossetti uses the example of a dry lemon to ensure that once the beta cells of the pancreas, in charge of insulin production, dry, no drug can avoid the outcome, although it leaves the door open to the possibility of delaying that situationto the maximum with other products.
